[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578782":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":24,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":24,"enrollmentInfo":61,"targetDuration":24,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":24,"overallStatus":71,"whyStopped":24,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bolus terlipressin","ACTIVE_COMPARATOR","2 mg initially every 4 hourly for 2 days and then 1 mg every 4 hrs.",[13],"Drug: Terlipressin Injectable Product",{"label":15,"type":16,"description":17,"interventionNames":18},"Continous Infusion of Terlipressin","EXPERIMENTAL","Administered as a continuous infusion at 4 mg\u002F24 hours. After 12 hours, if the hepatic venous pressure gradient (HVPG) does not show a reduction of less than 10%, increase the dose to 6 mg\u002F24 hours.",[13],[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Terlipressin Injectable Product",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Dr Khushboo Yadav, MD","CONTACT","01146300000","ky29277@gmail.com",{"name":32,"role":28,"phone":29,"phoneExt":24,"email":33},"Dr Vinod S Arora, DM","VINOD_UCMS@yahoo.com",[35],{"facility":36,"status":24,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Institute of Liver & Biliary Sciences (ILBS)","New Delhi","National Capital Territory of Delhi","110070","India","IN",{"type":43,"coordinates":44},"Point",[45,46],77.2148,28.62137,{"lat":46,"lon":45},[49],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100578782","phase-2-efficacy-and-safety-of-continuous-infusion-of-terlipressin-vs-bolus-terlipressin-in-aclf-patients-with-acute-esophageal-variceal-bleed-100578782",false,"NCT06815770","Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed","Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed: Pilot Study","Inclusion Criteria:\n\n1. Adult patients (age ≥ 18 years) diagnosed with ACLF presenting with due to esophageal varices bleeding.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. History of coronary heart disease or ventricular arrhythmia,\n3. Stroke or transient ischemic attack,\n4. Bronchial asthma,\n5. Epilepsy,\n6. Pregnancy,\n7. Rebleeding.\n8. HCC\n9. Gastric variceal bleed","ALL","18 Years",{"count":62,"type":63},60,"ESTIMATED","INTERVENTIONAL",[66,67],"PHASE2","PHASE3","Acute portal hypertension, as measured by rapid rise in hepatic venous pressure gradient (HVPG) can lead to further dreaded complications, including acute variceal bleeding (AVB) AVB: 6-week mortality rates of around 15-20% in patients with chronic liver disease without ACLF.The overall prevalence of UGH in cirrhotic patients with AD was 34.4% and 35.7% in patients with ACLF.AVB is a well-recognized precipitant leading to the occurrence and development of ACLF. AVB is a well-recognized precipitant leading to the occurrence and development of ACLF. Medical therapy for esophageal variceal bleeding (EVB) aims to reduce the splanchnic blood flow and portal pressure. The most common vasoactive agents include terlipressin, vasopressin, somatostatin, and octreotide.",[70],"Acute on Chronic Liver Failure","NOT_YET_RECRUITING","2025-02-06",{"date":74,"type":75},"2025-02-07","ACTUAL",{"date":77,"type":63},"2025-02-10",{"date":79,"type":63},"2026-02-28",{"name":5,"class":6},1]